Matrix metalloproteinase 2 and 9 in esophageal cancer: Correlation with organ metastasis

International Journal of Oncology

Volumn 8, Issue 4, 1996, Pages 773-779

  Kataoka, Masato ^a   Yamagata, Sadako ^b   Akiyama, Seiji ^a   Watanabe, Tadashi ^a   Takagi, Hiroshi ^a   Ayethant, Aye ^a   Iida, Ken Ichi ^a   Saga, Shinsuke ^a   Kishi, Jun Ichi ^c   Hamaguchi, Michinari ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c AICHI GAKUIN UNIVERSITY   (Japan)

Author keywords

Esophageal carcinoma; Gelatinase; MMP 2; MMP 9; Prognosis

Indexed keywords

AMINOPHENYLMERCURIC ACETATE; GELATINASE; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ESOPHAGUS CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; MALE; METASTASIS; PRIORITY JOURNAL;

EID: 0029879450     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Akiyama H, Tsurumaru M, Kawamura T and Ono Y: Principles of surgical treatment for carcinoma of the esophagus. Ann Surg 194: 436-438, 1981.
2. Sugimachi K, Matsusaka H, Ohno S, Mori M and Kuwano H: Multifactorial approach for assessing the prognosis of clinical oesophageal carcinoma. Br J Surg 75: 1115-1118, 1988.
3. Kato H, Tachimori Y, Watanabe H, Yamaguchi H, Ishikawa T and Itabashi M: Superficial esophageal carcinoma: surgical treatment and the results. Cancer 66: 2319-2323, 1990.
4. Barsky SH, Siegal GP, Jannotta F and Liotta LA: Loss of basement membrane components by invasive tumors but not by their benign counterparts. Lab Invest 49: 140-147, 1990.
5. Liotta LA, Tryggvason K, Garvisa S, Hart IR, Foltz CM and Shafie S: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284: 67, 1980.
6. Liotta LA and Stetler-Stevenson WG: Tumor invasion and metastasis, and imbalance of positive and negative regulation. Cancer Res 51: 5059-5064, 1991.
7. Liotta LA, Tryggvason K, Garbisa S, Robey PG and Abe S: Partial purification and characterization of a neutral protease which cleaves type IV collagen. Biochemistry 20: 100-104, 1981.
8. Hibbs MS, Hasty KA, Seyer JM, Kang AH and Mainardi CL: Biochemical and immunological characterization of the secreted forms of human neutrophil gelatinase. J Biol Chem 260: 2493-2500, 1985.
9. Stetler-Stevenson WG, Krutzsch HC, Wacher MP, Margulies IMK and Liotta LA: The activation of human type IV collagenase proenzyme. Sequence identification of the major conversion product following organomercurial activation. J Biol Chem 264: 1353-1356, 1989.
10. Mignatti P, Robbins E and Rifskin DB: Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade. Cell 47: 487-498, 1986.
11. He C, Wilheim SM, Pentland AP, Marmer BL, Grant GA, Eisen AZ and Goldberg GI: Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci USA 86: 2632-2636, 1989.
12. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E and Seiki M: A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 370: 61-65, 1994.
13. Thorgeirsson UP, Liotta LA, Kalebic T, Marugulies IM, Thomas K, Rios-Candelore M and Russo RG: Effect of natural protease inhibitors and a chemoattractant on tumor cell invasion. J Natl Cancer Inst 69: 1049-1054, 1982.
14. Goldberg GI, Marmer BL, Grant GA, Eisen AZ, Wilheim SM and He C: Human 72-kDa type IV collagenase forms a complex with a tissue inhibitor of metalloproteinases designated TIMP-2. Proc Natl Acad Sci USA 86: 8207-8211, 1989.
15. Turpeenniemi-Hujanen T, Thorgeirsson UP, Hart IR, Grant SS and Liotta LA: Expression of collagenase IV (basement membrane collagenase) activity in murine tumor cell hybrids that differ in metastatic potential. J Natl Cancer Inst 75: 99-103, 1985.
16. Garbisa S, Pozzatti R, Muschel RJ, Saffiotti U, Ballin M, Goldfarb RH, Khoury G and Liotta LA: Secretion of type IV collagenolytic protease and metastatic phenotype: induction by transfection with c-Ha-ras but not c-Ha-ras plus Ad2-E1a. Cancer Res 47: 1523-1528, 1987.
17. Ballin M, Gomez DE, Sinha CC and Thorgeirsson UP: Ras oncogene mediated induction of a 92-kDa metalloproteinase; strong correlation with the malignant phenotype. Biochem Biophys Res Commun 154: 832-838, 1988.
18. Bernhard EJ, Muschel RJ and Hughes EN: Mr 92,000 gelatinase release correlates with the metastatic phenotype in transformed rat embryo cells. Cancer Res 50: 3872-3877, 1990.
19. Van Der Stappen JWJ, Hendriks T and Wobbes T: Correlation between collagenolytic activity and grade of histological differentiation in colorectal tumors. Int J Cancer 45: 1071-1078, 1990.
20. Levy AT, Cioce V, Sobel ME, Garbisa S, Grigioni WF, Liotta LA and Stetler-Stevenson WG: Increased expression of the Mr 72,000 type IV collagenase in human colonic adenocarcinoma. Cancer Res 51: 439-444, 1991.
21. Yamagata S, Yoshii Y, Suh JG, Tanaka R and Shimizu S: Occurrence of an active form of gelatinase in human gastric and colorectal carcinoma tissues. Cancer Lett 59: 51-55, 1991.
22. Davies B, Miles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD and Balkwill FR: Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer 67: 1126-1131, 1993.
23. Brown PD, Bloxidge RE, Anderson E and Howell A: Expression of activated gelatinase in human invasive breast carcinoma. Clin Exp Metastasis 11: 183-189, 1993.
24. Brown PD, Bloxidge RE, Stuart NSA, Gatter KC and Carmichael J: Association between expression of activated 72-kDa gelatinase and tumor spread in non-small-cell lung carcinoma. J Natl Cancer Inst 85: 574-578, 1993.
25. Okada Y, Watanabe S, Nakanishi I, Kishi J, Hayakawa T, Watorek W, Travis J and Nagase H: Inactivation of tissue inhibitor of metalloproteinases by neutrophil elastase and other serine proteinases. FEBS Lett 229: 157-160, 1988.
26. Hamaguchi M, Yamagata S, Thant AA, Xiao H, Iwata H, Mazaki T and Hanafusa H: Augmentation of metalloproteinase (gelatinase) activity secreted from Rous sarcoma virus-infected cells correlates with transforming activity of src. Oncogene 10: 1037-1043, 1995.
27. Yamagata S, Ito Y, Tanaka R and Shimizu S: Gelatinases of metastatic cell lines of murine colonic carcinoma as detected by substrated-gel electrophoresis. Biochem Biophys Res Commun 151: 158-162, 1988.
28. src with Triton X-100-resistant cellular structure correlates with morphological transformation. Proc Natl Acad Sci USA 84: 2312-2316, 1987.
29. v-src causes tyrosine phosphorylation and inactivation of the N-cadherin-catenin cell adhesion system. EMBO J 12: 307-314, 1993.
30. Yamagata S, Tanaka R, Ito Y and Shimizu S: Gelatinases of murine metastatic tumor cells. Biochem Biophys Res Commun 158: 228-234, 1989.
31. Hermanek P and Sobin LH (eds): UICC International Union Against Cancer, TNM classification of malignant tumors. 4th edition. Springer, New York, 1987.
32. Oota K and Sobin LH: Histological typing of gastric and oesophageal tumors. In: International Histological Classification of Tumors. No. 18. World Health Organization. Geneva, Switzerland, 1977.
33. Isono K, Sato H and Nakayama K: Results of a nationwide study on the three-field lymph node dissection of esophageal cancer. Oncology 48: 411-420, 1991.
34. Lu X, Levy M, Weinstein BI and Santella RM: Immunological quantitation of levels of tissue inhibitor of metalloproteinase-1 in human colon cancer. Cancer Res 51: 6231-6235, 1991.